196 related articles for article (PubMed ID: 38613897)
41. Nicotinic acetylcholine receptors in chemotherapeutic drugs resistance: An emerging targeting candidate.
Afrashteh Nour M; Hajiasgharzadeh K; Kheradmand F; Asadzadeh Z; Bolandi N; Baradaran B
Life Sci; 2021 Aug; 278():119557. PubMed ID: 33930371
[TBL] [Abstract][Full Text] [Related]
42. Targeting JNK and its role in tumor development and chemoresistance.
Wu Q; Kuca K; Wu W
Future Med Chem; 2020 Jun; 12(12):1103-1105. PubMed ID: 32372662
[No Abstract] [Full Text] [Related]
43. The Role of MicroRNAs in the Chemoresistance of Breast Cancer.
Wang J; Yang M; Li Y; Han B
Drug Dev Res; 2015 Nov; 76(7):368-74. PubMed ID: 26310899
[TBL] [Abstract][Full Text] [Related]
44. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
45. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
46. Extracellular Vesicles in Chemoresistance.
De Rubis G; Bebawy M
Subcell Biochem; 2021; 97():211-245. PubMed ID: 33779919
[TBL] [Abstract][Full Text] [Related]
47. ATP-binding cassette efflux transporters and MDR in cancer.
Pote MS; Gacche RN
Drug Discov Today; 2023 May; 28(5):103537. PubMed ID: 36801375
[TBL] [Abstract][Full Text] [Related]
48. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
49. N6-methyladenosine RNA modification in cancer therapeutic resistance: Current status and perspectives.
Xu Z; Peng B; Cai Y; Wu G; Huang J; Gao M; Guo G; Zeng S; Gong Z; Yan Y
Biochem Pharmacol; 2020 Dec; 182():114258. PubMed ID: 33017575
[TBL] [Abstract][Full Text] [Related]
50. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
Rohwer N; Cramer T
Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
[TBL] [Abstract][Full Text] [Related]
51. Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability.
Eptaminitaki GC; Stellas D; Bonavida B; Baritaki S
Drug Resist Updat; 2022 Dec; 65():100866. PubMed ID: 36198236
[TBL] [Abstract][Full Text] [Related]
52. Autophagy-mediating microRNAs in cancer chemoresistance.
Jing Y; Liang W; Liu J; Zhang L; Wei J; Yang J; Zhang Y; Huang Z
Cell Biol Toxicol; 2020 Dec; 36(6):517-536. PubMed ID: 32875398
[TBL] [Abstract][Full Text] [Related]
53. What "The Cancer Genome Atlas" database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs.
Briz O; Perez-Silva L; Al-Abdulla R; Abete L; Reviejo M; Romero MR; Marin JJG
Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):577-593. PubMed ID: 31185182
[No Abstract] [Full Text] [Related]
54. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?
Fodale V; Pierobon M; Liotta L; Petricoin E
Cancer J; 2011; 17(2):89-95. PubMed ID: 21427552
[TBL] [Abstract][Full Text] [Related]
55. The role of long non-coding RNAs in mediating chemoresistance by modulating autophagy in cancer.
Jin KT; Lu ZB; Lv JQ; Zhang JG
RNA Biol; 2020 Dec; 17(12):1727-1740. PubMed ID: 32129701
[TBL] [Abstract][Full Text] [Related]
56. Predicting and Overcoming Taxane Chemoresistance.
Rodrigues-Ferreira S; Moindjie H; Haykal MM; Nahmias C
Trends Mol Med; 2021 Feb; 27(2):138-151. PubMed ID: 33046406
[TBL] [Abstract][Full Text] [Related]
57. Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives.
Zahan T; Das PK; Akter SF; Habib R; Rahman MH; Karim MR; Islam F
Anticancer Agents Med Chem; 2020; 20(18):2190-2206. PubMed ID: 32748758
[TBL] [Abstract][Full Text] [Related]
58. Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer.
Maji S; Panda S; Samal SK; Shriwas O; Rath R; Pellecchia M; Emdad L; Das SK; Fisher PB; Dash R
Adv Cancer Res; 2018; 137():37-75. PubMed ID: 29405977
[TBL] [Abstract][Full Text] [Related]
59. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.
Peng H; Dong Z; Qi J; Yang Y; Liu Y; Li Z; Xu J; Zhang JT
PLoS One; 2009 May; 4(5):e5676. PubMed ID: 19479068
[TBL] [Abstract][Full Text] [Related]
60. Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy.
He C; Li L; Guan X; Xiong L; Miao X
Chemotherapy; 2017; 62(1):43-53. PubMed ID: 27322648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
